Savara Inc
Close on Oct 19, 2026
- Market cap
- $1.17B
- P/E (TTM)
- –
- Dividend yield
- –
About Savara
Pharmaceutical Preparations, SIC 2834
Savara Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. The company's sole program is molgramostim inhalation solution, an investigational biologic consisting of inhaled granulocyte-macrophage colony-stimulating factor. It is being developed specifically to treat autoimmune pulmonary alveolar proteinosis, a rare condition that causes surfactant accumulation within the lungs' air sacs. Molgramostim delivers the therapeutic formulation using an exclusive, proprietary nebulizer system, with patients afflicted by this rare autoimmune condition serving as its primary target population.
The company operates without internal commercial manufacturing facilities, relying on third-party contract organizations to supply drug substance, produce drug products, and provide the inhalation delivery devices across clinical testing phases. Savara maintains its principal executive offices in Langhorne, Pennsylvania. Beyond its operations in the United States, the company's activities involve foreign suppliers and research initiatives spanning Europe, the United Kingdom, and Japan.
Summary of the business section of Savara's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Savara Inc
- Headquarters
- Austin, TX
- Address
- 6836 Bee Cave Road, Building 3, Suite 201 78746
- Phone
- 51285113796
- Website
- savarapharma.com
- Employees
- 70, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- RSM US LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- SVRA
- Exchange
- Nasdaq
- IPO date
- Apr 28, 2017
- Shares outstanding
- 205M, Aug 11, 2026
- Public float
- $544.46M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-70 reverse, May 9, 2017
- SEC CIK
- 1160308
- CUSIP
- 805111101
- ISIN
- US8051111016
- LEI
- 5493002JO0WM3YMJXG33
- EIN
- 84-1318182
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Matthew Pauls | CHIEF EXECUTIVE OFFICER, Director | 1,188,050 |
| Braden C. Parker | Chief Commercial Officer | 75,677 |
| Robert Matthew Lutz | Chief Fin. & Operating Officer | 328,977 |
| David L. Lowrance | Chief Financial Officer | 953,968 |
| Kathleen R. McCabe | Chief Legal Officer | 519,232 |
| Anne Erickson | Chief Business Officer | 371,712 |
| Yasmine Wasfi | Chief Medical Officer | 168,008 |
| Raymond Dennis Pratt | Chief Medical Officer | 340,050 |
| Joseph S. McCracken | Director | 302,644 |
| David A. Ramsay | Director | 2,533,642 |
| Richard J. Hawkins | Director | 161,326 |
| Es-Johansson An van | Director | 102,500 |
| Nevan C. Elam | Director | 106,887 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr. Pauls | $4.85M | $9.89M | $2.39M | $196 | – |
| FY2024 Mr. Pauls | $4.91M | $3.97M | $1.87M | $65 | – |
| FY2023 Mr. Pauls | $3.76M | $5.66M | $2.09M | $303 | – |
| FY2022 Mr. Pauls | $2.20M | $2.51M | $876.41K | $125 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 13, 2026, we had approximately 70 employees as well as several third-party consultants.”
Corporate history
Events identified from SEC filings